Q1 Earnings Estimate for MRKR Issued By HC Wainwright

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Marker Therapeutics in a report released on Friday, March 20th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Marker Therapeutics’ Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.30) EPS and FY2030 earnings at ($0.75) EPS.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.17. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.68 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%.

A number of other brokerages also recently issued reports on MRKR. Zacks Research downgraded shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. Wall Street Zen upgraded shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Marker Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.

Marker Therapeutics Stock Performance

Shares of NASDAQ:MRKR opened at $1.34 on Monday. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.07. The business has a 50-day simple moving average of $1.59 and a two-hundred day simple moving average of $1.30. The firm has a market cap of $22.34 million, a price-to-earnings ratio of -1.58 and a beta of 1.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in shares of Marker Therapeutics during the 3rd quarter valued at about $25,000. Two Sigma Investments LP bought a new position in shares of Marker Therapeutics in the 3rd quarter worth approximately $33,000. Jane Street Group LLC bought a new position in shares of Marker Therapeutics in the 2nd quarter worth approximately $33,000. Boyer Financial Services Inc. purchased a new position in shares of Marker Therapeutics in the fourth quarter worth approximately $57,000. Finally, XTX Topco Ltd boosted its holdings in shares of Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after buying an additional 36,269 shares during the last quarter. 22.39% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Marker Therapeutics

Here are the key news stories impacting Marker Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $10.00 price target while publishing detailed quarterly and long‑term EPS model updates — a high-profile analyst backing that can attract buyers and liquidity. HC Wainwright research (via MarketBeat)
• Positive Sentiment: Brookline Cap M boosted its FY2026 EPS forecast for MRKR (revising the year loss from roughly ($2.74) to ($1.53)), signaling expectations for a smaller-than-previously-forecast cash burn or improved near‑term operating performance. Brookline Cap M note (via MarketBeat)
• Neutral Sentiment: HC Wainwright published quarterly EPS forecasts for 2027 (Q1: ($0.33), Q2: ($0.36), Q3: ($0.38), Q4: ($0.30)) and a FY2030 EPS view of ($0.75) — useful modeling inputs but they still project ongoing losses for several years. HC Wainwright forecasts (via MarketBeat)
• Neutral Sentiment: Aggregator coverage summarized analyst Q2 forecasts for MRKR; these consensus/estimates pieces are informational and help set expectations ahead of upcoming reports. Equities Analysts Issue Forecasts for MRKR Q2 Earnings
• Negative Sentiment: Consensus still forecasts a full‑year loss (approx. ($0.65) EPS), and quarter-by-quarter models remain negative — continued losses and negative margins could limit valuation multiple expansion and keep the stock volatile. Consensus estimates (via MarketBeat)
• Negative Sentiment: Historical metrics show large negative margins and negative ROE (company remains unprofitable), meaning any deterioration in operating results or funding concerns would weigh on the share price. Company fundamentals (via MarketBeat)

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.